Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Altimmune, Inc. has received an average recommendation of "Moderate Buy" from analysts, with five buy ratings, one hold, and one sell.
• The average price target for the stock among analysts is $17.40, though recent reports have seen price targets adjusted downwards.
• Altimmune recently reported quarterly earnings of ($0.27) per share, which beat analyst expectations of ($0.32), indicating better-than-anticipated performance.

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $17.40.

ALT has been the subject of several research reports. B. Riley reduced their price objective on Altimmune from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. JMP Securities reduced their price objective on Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a research report on Thursday, July 10th. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research report on Wednesday, August 13th. William Blair reissued a "market perform" rating on shares of Altimmune in a research report on Friday, June 27th. Finally, UBS Group reduced their price objective on Altimmune from $26.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th.

Altimmune Price Performance

NASDAQ:ALT traded down $0.10 during trading hours on Wednesday, hitting $3.53. 1,910,115 shares of the company's stock traded hands, compared to its average volume of 2,903,875. Altimmune has a twelve month low of $2.90 and a twelve month high of $11.16. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09. The stock's fifty day moving average price is $4.58 and its two-hundred day moving average price is $5.21.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. On average, sell-side analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Several large investors have recently modified their holdings of ALT. Ameriprise Financial Inc. increased its position in shares of Altimmune by 35.6% in the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the period. Federated Hermes Inc. boosted its position in Altimmune by 387.7% during the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock valued at $3,543,000 after acquiring an additional 727,731 shares during the last quarter. Bank of America Corp DE increased its holdings in Altimmune by 155.2% in the second quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock worth $2,771,000 after purchasing an additional 435,467 shares in the last quarter. RFG Advisory LLC acquired a new stake in Altimmune in the first quarter worth $1,622,000. Finally, Nuveen LLC bought a new position in Altimmune in the first quarter worth approximately $1,304,000. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.